-
Mashup Score: 0Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma - 15 hour(s) ago
This article reports a patient with pancreatic neuroendocrine carcinoma with a finding of a nuclear receptor co-activator 4-RET fusion and subsequent treat
Source: academic.oup.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 18Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib - 3 day(s) ago
The case of an adult patient with a recurrent medulloblastoma is presented, that showed a 1-year-long benefit with second-line vismodegib, and where serial
Source: academic.oup.comCategories: General Medicine News, Oncologists1Tweet-
Precision Medicine Clinic: Molecular Tumor Board The case of a patient with recurrent medulloblastoma, showing long-lasting benefit with #vismodegib, is presented, demonstrating the feasibility of #PTCH1-mutation tracking in #plasma. @SantiCabezas1 https://t.co/nC79RJxiL5
-
-
Mashup Score: 12
AbstractIntroduction. Among older adults with cancer receiving chemotherapy, frailty indices predict OS and toxicity. Given the increased use of immunother
Source: academic.oup.comCategories: General Medicine News, Oncologists1Tweet-
#Frailty over performance predicts not just #OS but also 🏥 stay & #tox in older adults 👴👵 w/ #NSCLC on #chemo💉💊#GeriOnc. Frail patients had ⬇️ #OS (HR 2.09) & ⬆️hospitalization. @AnaVManana @GrantWilliamsMD @AlexSmithMD https://t.co/xRbZKrQ6Y7 https://t.co/EFGwP7pLef
-
-
Mashup Score: 10
AbstractBackground. Atezolizumab plus bevacizumab (A/B) received FDA approval as the first-line therapy for patients with advanced hepatocellular carcinoma
Source: academic.oup.comCategories: General Medicine News, Oncologists1Tweet-
Study of advanced #hpbcsm HCC patients treated with #atez+ #bev found no #OS difference between 2nd line #ICI or #VEGFi therapies. Median #OSwas 11.1 months. CPS remains 🔑 for prognosis. @GIcancerDoc #GIonc https://t.co/GoelX7VpkW https://t.co/FVMIcng0ho
-
-
Mashup Score: 6Supporting patients with advanced cancer and their spouses in parenting minor children: results of a randomized controlled trial - 8 day(s) ago
AbstractIntroduction. Patients with advanced cancer and their spousal caregivers who parent minor children report unmet parenting concerns and increased ps
Source: academic.oup.comCategories: General Medicine News, Oncologists1Tweet-
#RCT investigated a novel psychosocial intervention for advanced cancer pts & caregivers in parenting. It met feasibility showing ⬇️anxiety while ⬆️parenting efficacy. Notable high attendance w/ ✚feedback could address unmet needs. #supponc @BrueraEduardo https://t.co/EcwXpEKZgH
-
-
Mashup Score: 11
Mrs A., at the age of 58 years, was referred by her oncologist to the early palliative care (EPC) outpatient ambulatory clinic of our cancer center in Mode
Source: academic.oup.comCategories: General Medicine News, Oncologists1Tweet-
A lovely narrative from our 🇮🇹colleagues describing a #bcsmsurvivor seeking #pallonc, finding relief in art & open discussions on #EoL Her pain was controlled & through compassionate care she & her team found solace in the Madonna del Parto. @BrueraEduardo https://t.co/TA96stXR5D https://t.co/ExJrha8FEI
-
-
Mashup Score: 16
AbstractBackground. Patients with a germline BRCA pathogenic variant (gBRCA-PV) and advanced high grade ovarian carcinoma (aHGOC) experience higher hematol
Source: academic.oup.comCategories: General Medicine News, Oncologists1Tweet-
Patients with #OvarianCancer and a germline #BRCA pathogenic variant (gBRCA-PV) do not experience higher hematological AEs vs. non-gBRCA-PV carriers while on #PARPinhibitor therapy. @curijoey @ValenzaCarmine @darioT_ https://t.co/BJBJgrHvYE https://t.co/E6HHfnOQ8M
-
-
Mashup Score: 9Evidence for the benefits of lifestyle medicine interventions in breast cancer survivorship - 1 month(s) ago
Abstract. There are currently 4 million breast cancer survivors in the United States, and this number is expected to substantially increase in the decades
Source: academic.oup.comCategories: General Medicine News, Oncologists1Tweet-
This review provides evidence for survival and QoL benefits in patients with #BreastCancer through the 6 pillars of lifestyle medicine: @OSUWexMed https://t.co/hJO8sX11Ul https://t.co/Zh7UeuBAgK
-
-
Mashup Score: 13Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study - 1 month(s) ago
AbstractBackground. Venous thromboembolism (VTE) is one of the leading causes of death in patients with cancer. Currently, there is a need to develop an ea
Source: academic.oup.comCategories: General Medicine News, Oncologists1Tweet-
Based on the #CARTAGO model, these variables may predict #VTE risk in pts w/ cancer undergoing outpatient treatment & help identify those who need 1° thromboprophylaxis: 1️⃣ Tumor type 2️⃣ D-dimer 3️⃣ Vessel compression by tumor 4️⃣ WBC count @PabloCerezuela https://t.co/1kWv46rauP https://t.co/1R9eJpa3L1
-
-
Mashup Score: 6Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer - 1 month(s) ago
AbstractBackground. Biliary tract cancer (BTC) is an aggressive biliary tract cancer, arising from the bile ducts and gallbladder, with a poor prognosis. T
Source: academic.oup.comCategories: General Medicine News, Oncologists1Tweet-
A #realworld #GIonc trial from our 🇨🇳 colleagues based on #TOPAZ1 💎 protocol (durvalumab + cisplatin + gemcitabine) in #hpbcsm. Median #OS 15.8 mo with ⬇️ECOG and neutrophil-lymphocyte ratio linked to ⬇️ prognosis. https://t.co/GbUPUa3sNf https://t.co/7fCat73FXE
-
Report of a patient with pancreatic neuroendocrine carcinoma and the finding of a RET fusion. Clinical course highlights that finding a targetable alteration does not always = benefit to the patient. @drjasonstarr https://t.co/oS4Y9LSLr2 https://t.co/vBJ12u8Icv